Relmada Therapeutics, Inc. Announces Change of its Corporate Headquarter
January 04, 2019 at 05:10 pm EST
Share
Effective January 1, 2019, Relmada Therapeutics, Inc. changed its corporate headquarters to 880 3rd Ave, 12th floor, New York, NY 10022. Pursuant to a Lease Agreement, effective January 1, 2019 between the Company and 880 Third Avenue Tenant LLC, the company now occupies a portion of the 12th Floor at 880 3rd Ave, New York, NY 10022.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
RELMADA THERAPEUTICS, INC. 
